Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2015
At a glance
- Drugs Sunitinib (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 28 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Feb 2017 as reported by ClinicalTrials.gov.